Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841938 | 1.00 | BLM (0.37) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL560809 | 1.00 | BLM (0.37) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL7120217 | 0.98 | BLM (0.34) | BLMPMP22HSD17B10 | |
| SCHEMBL21070958 | 0.85 | MEN1 (0.37) | KDM4E | |
| SCHEMBL17183915 | 0.84 | BLM (0.34) | BLMPMP22HSD17B10 | |
| SCHEMBL21070941 | 0.84 | MEN1 (0.41) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL16353668 | 0.84 | KDM4E (0.42) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL18689524 | 0.84 | KDM4E (0.42) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL16353619 | 0.84 | MEN1 (0.41) | BLMPMP22HSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL4699208 | 0.83 | HSD17B10 (0.36) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| EP-3828164-B1 | NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME | AUTOTAC INC (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-20240174772-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-11932708-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-20210299253-A1 | NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME | PROTECH CO., LTD. (KR) | 2021-09-30 | — | — | US | disclosed |
| EP-3808783-A1 | NOVEL CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-04-21 | — | — | EP | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-9295729-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2016-03-29 | — | — | US | disclosed |
| EP-2889624-A2 | Reversible covalent linkage of functional molecules | UCL Business PLC (GB) | 2015-07-01 | — | — | EP | disclosed |
| EP-2549276-B1 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2549276-A2 | Reversible covalent linkage of functional molecules | UCL Business PLC (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120115128-A1 | SELECTIVE PROTEIN LABELING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) | 2012-05-10 | — | — | US | disclosed |
| WO-2011059586-A2 | MULTIFUNCTIONAL SMALL MOLECULES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010129929-A1 | SELECTIVE PROTEIN LABELING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | BLM 2017/4885PMP22 4610/4885HSD17B10 1343/4885 |
| US-20120190579-A1 | Functionalisation of Solid Substrates | XDH, SPR, DAO | BLM 3168/4885PMP22 3199/4885HSD17B10 1684/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | BLM 1952/4885PMP22 4507/4885HSD17B10 4388/4885 |
| US-20210299253-A1 | NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME | ATG7, SQSTM1, CTSA | BLM 3107/4885PMP22 3421/4885HSD17B10 3484/4885 |
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | BLM 3348/4885PMP22 4181/4885HSD17B10 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.